Lisaftoclax

A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination With Azacitidine (AZA) in Patients With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4).

Arms / Cohorts

Experimental:Lisaftoclax (APG-2575) combined with Azacitidine

Status
Status not available
Treatments
Treatments not available
Criteria
Criteria not available

Not yet accepting

Active Comparator:Placebo combined with Azacitidine

Status
Status not available
Treatments
Treatments not available
Criteria
Criteria not available

Not yet accepting

Patient Screener(888) 803-1766

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.